1. iosensors DES Demonstrates Superior Strut Coverage to Industry Leading DES

    In the first study of its kind, a new medical imaging technique showed that lesions treated with a Biosensors’ biolimus drug eluting stent (DES) were more than 10 times more likely to have nearly-complete stent-strut coverage at nine months than those treated with the industry standard DES. Uncovered stent struts may disrupt blood flow within the vessel and could be a contributing factor towards stent thrombosis. The results of the Optical Coherence Tomography (OCT) sub-set analysis, comparing post-implantation tissue coverage between two drug-eluting stents (DES) in a large-scale, randomized trial, were presented on 14 October at the 2008 Transcatheter Cardiovascular ...

    Read Full Article

    Login to comment.

  1. Categories

    1. Applications:

      Art, Cardiology, Dentistry, Dermatology, Developmental Biology, Gastroenterology, Gynecology, Microscopy, NDE/NDT, Neurology, Oncology, Ophthalmology, Other Non-Medical, Otolaryngology, Pulmonology, Urology
    2. Business News:

      Acquisition, Clinical Trials, Funding, Other Business News, Partnership, Patents
    3. Technology:

      Broadband Sources, Probes, Tunable Sources
    4. Miscellaneous:

      Jobs & Studentships, Student Theses, Textbooks
  2. Quotes

    1. I am very happy with the 12-month results of the LEADERS study, which confirm the 9-month results. The Biosensors drug eluting stent, combining the novel biolimus drug and an abluminal biodegradable polymer, is a very promising technology for our patients long term benefit
  3. Topics Mentioned